News | February 04, 2026
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Subscribe To Our Newsletter & Stay Updated
